In this webinar, we will discuss the issues set to shape the biopharma industry over the next 12 months. Following the recent release of the 2023 Preview Report, Evaluate Vantage's Amy Brown and Edwin Elmhirst will take a deeper dive into the data from 2022 and discuss the key factors influencing the outlook for the coming year.
Highlights
- Innovation and regulation: what developments lie ahead?
- Growing biopharma's top line: which drugs and companies will lead the pack?
- Something new: what are the R&D projects and potential launches to look out for?
- Positive signs: where are they coming from?
Your Hosts:
Amy Brown,
Deputy Editor, Evaluate Vantage
Deputy Editor, Evaluate Vantage
Edwin Elmhirst,
Data Journalist, Evaluate Vantage
Data Journalist, Evaluate Vantage
